Tanabe Pharma Factory

Tanabe Pharma Factory Co., Ltd. is the primary manufacturing subsidiary of Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma), a leading Japanese pharmaceutical company. Headquartered in Osaka, the company operates several high-capacity, GMP-compliant manufacturing sites across Japan, including facilities in Onoda, Yoshitomi, and Ashikaga. It specializes in the production of diverse therapeutic modalities such as small molecules, vaccines, and injectable biologics, supporting the parent company's focus on the central nervous system, immunology, and rare diseases. Following the acquisition of the Mitsubishi Tanabe Pharma Group by Bain Capital in 2025, the factory was rebranded from Mitsubishi Tanabe Pharma Factory to its current name. The company is recognized for its advanced quality control technologies, including near-infrared hyperspectral imaging, and its role in the global supply of critical treatments like Radicava for ALS.